학술논문
European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma
Document Type
Review Article
Author
Source
In ESMO Open 2020 5(6)
Subject
Language
ISSN
2059-7029